Anteris Technologies (AVR) Cash Funds per Single Share

Anteris Technologies Global develops biomimetic heart valves, with the cash per share on the GURU.Markets chart recorded at 2.38, confirming the financial stability of the R&D stage. Material patents and FDA certification create significant barriers to entry. The innovative 3D architecture of aortic valve prostheses provides the company with protection against competitor dumping.
Comprehensive metric breakdowns and analytics for Anteris Technologies Global (AVR)

Cash per share determines the volume of highly liquid reserves attributable to a single security, allowing for an assessment of the company's intrinsic value and financial autonomy. By analyzing the trend of liquid assets per share, an investor can see the impact of expenses on the balance sheet, which is critical for Anteris Technologies Global (AVR) when financing prolonged clinical trials for cardiac surgery products regardless of market conditions.